Figures computed from official regulatory filings — .
Analysttarget 2 USD (+55%) · consensus 3/5 · 0 buy · 2 hold · 0 sell
Ownershipinsiders 44.56% · institutions 51.68% · short 17.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Organogenesis Holdings Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
76 buys83 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Grow Brian | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grow Brian | Exercise | $1.2K | SEC |
| Driscoll Michael Joseph | Buy | $26.7K | conv 53First in 12mo | SEC |
| Leibowitz Arthur S | Buy | $13.4K | conv 39First in 12mo | SEC |
| Cavorsi Robert | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Freedman Lori | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grow Brian | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grow Brian | Other | $45.6K | SEC |
| Bilbo Patrick | Other | $62.9K | SEC |
| Gillheeney Gary S. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bilbo Patrick | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cavorsi Robert | Other | $21.1K | SEC |
| Montecalvo Antonio S. | Other | $14.5K | SEC |
| Francisco David | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Francisco David | Other | $56.4K | SEC |
| Freedman Lori | Other | $55.3K | SEC |
| Montecalvo Antonio S. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cavorsi Robert | Other | $2.2K | SEC |
| Gillheeney Gary S. | Other | $350.6K | SEC |
| Cavorsi Robert | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Francisco David | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bilbo Patrick | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grow Brian | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bilbo Patrick | Other | $62.3K | SEC |
| Bilbo Patrick | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |